KYMR Completes Enrollment
Kymera Therapeutics completes enrollment in the Phase 2b BROADEN2 trial of KT-621 in atopic dermatitis with topline data expected by year-end 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.